Revenue: FPH reported a 10% rise in revenue to $1.74 billion as growth returns to pre-Covid patterns.
Profit: Net profit after tax dropped 56% to $132.6 million after three abnormal items, while underlying profit rose 6% to $264.4m.
Key takeaway: The company is forecasting revenue for FY2025 of between $1.9 billion and $2 billion, net profit after tax of $310 million to $360m, and a lowered capital expenditure of around $150m. The assumption is based on a further improvement in gross margin based on historical pre-Covid levels.
It took 50 years for Fisher & Paykel Healthcare (FPH) to hit the milestone $1 billion revenue mark in 2019.
Five years later the respiratory healthcare company has given guidance of hitting close to double that – $1.9 billion to $2b in operating revenue for the 2025 financial year as growth rates
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Revenue: FPH reported a 10% rise in revenue to $1.74 billion as growth returns to pre-Covid patterns.
Profit: Net profit after tax dropped 56% to $132.6 million after three abnormal items, while underlying profit rose 6% to $264.4m.
Key takeaway: The company is forecasting revenue for FY2025 of between $1.9 billion and $2 billion, net profit after tax of $310 million to $360m, and a lowered capital expenditure of around $150m. The assumption is based on a further improvement in gross margin based on historical pre-Covid levels.
